Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonist

Area of Science:

• Endocrinology
• Metabolic Research
• Pharmacology

Background:

• Obesity and type 2 diabetes are linked to altered adiponectin signaling.
• Beta3-adrenoceptor agonists have shown potential in metabolic disease management.
• Understanding the molecular effects of these agonists is crucial for therapeutic development.

Purpose of the Study:

• To investigate the impact of the beta3-adrenoceptor agonist CL-316,243 on adiponectin and its receptor expression in a mouse model of diabetes (db/db mice).
• To assess the effects of CL-316,243 on metabolic parameters including glucose, insulin, and lipid levels.

Main Methods:

• Administration of CL-316,243 to db/db mice for two weeks.
• Measurement of plasma levels of hemoglobin A1c, glucose, insulin, triglyceride, free fatty acid, and adiponectin.
• Assessment of mRNA expression for adiponectin, adiponectin receptor 1, and adiponectin receptor 2 in various tissues (epididymal white adipose tissue, brown adipose tissue, soleus muscle, liver).
• Evaluation of insulin resistance using an oral glucose tolerance test.

Main Results:

• CL-316,243 treatment significantly reduced hemoglobin A1c, glucose, insulin, triglyceride, and free fatty acid levels.
• Plasma adiponectin levels were increased following CL-316,243 administration.
• Insulin resistance was improved in the treated mice.
• Adiponectin mRNA expression increased in epididymal white adipose tissue but not in other examined tissues.
• Adiponectin receptor 2 mRNA expression was significantly decreased in the liver of treated mice.

Conclusions:

• The beta3-adrenoceptor agonist CL-316,243 effectively improves metabolic parameters and insulin resistance in db/db mice.
• Increased plasma adiponectin levels induced by CL-316,243 are associated with altered adiponectin and adiponectin receptor 2 mRNA expression, particularly a down-regulation of adiponectin receptor 2 in the liver.